<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888069</url>
  </required_header>
  <id_info>
    <org_study_id>CTAP101-CL-2004</org_study_id>
    <nct_id>NCT00888069</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects</brief_title>
  <official_title>A Randomized, Open-Label, Single-Dose Pilot Study of Oral and i.v. CTAP101 Evaluating PK and Safety in Stage 3 and 4 CKD Subjects With Vitamin D Insufficiency and SHPT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO IP Holdings II, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate how the levels of a single dose of CTAP101 changes in the body
      over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances
      (pharmacodynamics, PD) in patients with Stage 3 or 4 chronic kidney disease (CKD) with
      vitamin D insufficiency and secondary hyperparathyroidism (SHPT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the PK and bioavailability of CTAP101 in Stage 3 and 4 CKD subjects with vitamin D insufficiency and SHPT</measure>
    <time_frame>from 3 to 0 hours prior to dosing until 42 days post dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of CTAP101 capsules and injection</measure>
    <time_frame>From signing of ICF (Day -35) through study completion (Day 42 post dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamics of single dose CTAP101 in Stage 3 and Stage 4 CKD subjects with vitamin D insufficiency and SHPT.</measure>
    <time_frame>From signing of ICF (Day -35) through study completion (Day 42 post dosing)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <condition>Chronic Renal Insufficiency</condition>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Low Dose CTAP101 Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTAP101 Capsules, 450 mcg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose CTAP101 Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTAP101 Capsules, 900 mcg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV injection, 448 mcg dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTAP101 Capsules</intervention_name>
    <description>Single dose oral administration</description>
    <arm_group_label>Low Dose CTAP101 Capsules</arm_group_label>
    <arm_group_label>High Dose CTAP101 Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTAP101 Injection</intervention_name>
    <description>single IV injection</description>
    <arm_group_label>CTAP101 Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index between great than or equal to 18 and less than or equal to 40 kg/m2

          -  Plasma iPTH value for Stage 3 CKD greater than or equal to 70 pg/mL and lower than or
             equal to 1000 pg/mL

          -  Plasma iPTH value for Stage 4 CKD greater than or equal to 110 pg/mL and lower than or
             equal to 1000 pg/mL

          -  Adjusted serum total calcium value greater than 8.4 mg/dL and lower than 10.0 mg/dL

          -  Serum phosphorus value greater than or equal to 2.5 mg/dL and lower than or equal to
             5.5 mg/dL

          -  Serum 25-hydroxyvitamin D level greater than 15 ng/mL and lower than 30 ng/mL

          -  Hemoglobin level greater than or equal to 10 g/dL

        Exclusion Criteria:

          -  Has nephrotic range proteinuria

          -  Has liver disease or significant hepatic dysfunction

          -  Is taking Cytochrome P450 3A4 inhibitors or inducers

          -  Has adult history of kidney stones and dysphagia

          -  Has known history of alcohol/controlled substance abuse or are positive for drug of
             abuse screen

          -  Currently on dialysis

          -  Current serious illness such as cancer, HIV, cardiovascular event or hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Melnick, MD</last_name>
    <role>Study Director</role>
    <affiliation>OPKO Renal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pivotal Research Centers</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research by Design</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western New England Renal &amp; Transplant Associates</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twin Cities Clinical Research</name>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCI</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109-1998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Houston Research Ltd</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Purity Dialysis Centers / Nephrology Associates</name>
      <address>
        <city>Delafield</city>
        <state>Wisconsin</state>
        <zip>53018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunderson Clinic Ltd.</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parathyroid Diseases</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Hyperparathyroidism, Secondary</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Hyperparathyroidism</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Kidney Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

